从肠道微生态探讨中药作用机制新模式

李景南; 徐甜

doi:10.3969/j.issn.1671-038X.2023.12.02

从肠道微生态探讨中药作用机制新模式

李景南¹,
徐甜¹

- 中国医学科学院北京协和医院消化内科中国医学科学院肠道微生态临床疾病转化研究重点实验室(北京，100730)
基金项目:
国家自然科学基金面上项目(No：82270567)；北京协和医院中央高水平医院临床科研专项(No：2022-PUMCH-B-022、2022-PUMCH-D-002)；中国医学科学院医学与健康科技创新工程(No：2021-I2M-1-003)

详细信息

作者简介:
李景南，北京协和医院消化内科副主任、主任医师、教授、博士生导师。北京协和医院一线临床工作30余年，期间作为访问学者赴美国哈佛医学院麻省总医院消化科进修3年。具有较丰富的临床工作经验，掌握各种消化系统常见疾病和疑难疾病的诊断及治疗；主持制定了《胃肠胰腺神经内分泌肿瘤诊治专家共识》、《胃肠道黏膜保护临床专家共识》，参与了亚太和全国结直肠癌筛查、预防、治疗以及其他多个临床共识及指南的制定；在胃肠神经内分泌肿瘤、肠道菌群与肠道疾病、结直肠癌筛查和预防方面进行了大量基础和临床研究；发表论著近百篇，承担5项国自然课题。担任《中国中西医结合消化杂志》副主编。参与多项国家重大研发计划。目前担任中国医师协会消化医师分会副会长，中华医学会消化病学分会副主任委员，北京医学会消化病学分会主任委员，中国中西医结合学会消化系统疾病专业委员会副主任委员等多项学术任职

中图分类号: R285

收稿日期: 2023-10-09

刊出日期: 2023-12-15

To explore the new mode of action mechanism of Traditional Chinese Medicine from intestinal microecology

LI Jingnan¹,
XU Tian¹

- Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China

Received Date: 09 October 2023

Publish Date: 15 December 2023

摘要

摘要: 中药是我国独特的医疗资源与科技资源，但中药的作用机制尚未得到充分揭示，极大限制了中药的创新发展。中药与西药(以化学药物为主)在药物起源、发现过程、指导理论、作用特点等方面明显不同。套用现有西药研究模式探讨中药的作用机制，往往力不从心。肠道微生态是一个被普遍忽略了的“器官”，影响着宿主健康。本文从肠道微生态出发，分析了以肠道微生态为中心的中药间接作用机制的多种科学模型，为深刻揭示中药作用机制，推进新药研发指明方向。
- 中药 /
- 肠道微生态 /
- 代谢产物 /
- 间接作用
Abstract: Traditional Chinese Medicine(TCM) is a unique medical resource and scientific and technological resource in China. However, the mechanism of action of TCM has not been fully revealed, which greatly limits the innovation and development of TCM. TCM and Western medicine(mainly chemical drugs) are different in the origin, discovery process, guiding theory, and action characteristics. It is often not enough to explore the mechanism of action of TCM using the existing research model of Western medicine. Intestinal microecology is a generally ignored "organ" that affects the health of the host. From the perspective of intestinal microecology, this paper analyzes a variety of scientific models of the indirect action mechanism of TCM with intestinal microecology as the center, to reveal the mechanism of TCM and promote the research and development of new drugs.
- Traditional Chinese Medicine /
- intestinal microecology /
- metabolites /
- indirect effect

HTML全文

参考文献(39)

[1]	李沐涵, 李景南. 溃疡性结肠炎癌变相关机制研究进展[J]. 中国中西医结合消化杂志, 2023, 31(4): 243-249. doi: 10.3969/j.issn.1671-038X.2023.04.02
[2]	周杨, 王嘉昀, 赵月, 等. 基于文献对肠道微生态在中医药领域研究热点与趋势分析[J]. 医药导报, 2022, 41(8): 1130-1140. https://www.cnki.com.cn/Article/CJFDTOTAL-YYDB202208010.htm
[3]	李焱, 林泳峰, 刘文美, 等. 食药同源植物多糖调控肠道稳态的研究进展[J]. 食品安全质量检测学报, 2023, 14(2): 25-33. https://www.cnki.com.cn/Article/CJFDTOTAL-SPAJ202302004.htm
[4]	Vincent F, Nueda A, Lee J, et al. Publisher Correction: Phenotypic drug discovery: recent successes, lessons learned and new directions[J]. Nat Rev Drug Discov, 2022, 21(7): 541. doi: 10.1038/s41573-022-00503-6
[5]	Wu Y, Zhang F, Yang K, et al. SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping[J]. Nucleic Acids Res, 2019, 47(D1): D1110-D1117. doi: 10.1093/nar/gky1021
[6]	张爱娟, 刘嘉辉, 王万春, 等. 脾胃学说在中医临床中的应用及展望[J]. 新中医, 2020, 52(7): 19-22. https://www.cnki.com.cn/Article/CJFDTOTAL-REND202007006.htm
[7]	李梢, 汪博洋, 曹亮, 等. 基于网络靶标理论和技术的中药研发实践[J/OL]. 中国中药杂志, https://doi.org/10.19540/j.cnki.cjcmm.20230923.701.
[8]	石任兵, 王永炎. 自然药学观的相关性思考[J]. 北京中医药大学学报, 2012, 35(4): 221-225. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYB201503001.htm
[9]	柏兆方, 覃双林, 赵旭, 等. 中西医融合创新: 系统辨靶论治[J]. 科学通报, 2021, 66(36): 4601-4607. https://www.cnki.com.cn/Article/CJFDTOTAL-KXTB202136002.htm
[10]	王伽伯, 肖小河. 中药的间接调控作用与间接作用型中药的创新发展[J]. 中国中药杂志, 2021, 46(21): 5443-5449. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY202121001.htm
[11]	沙珊珊, 董世荣, 杨玉菊. 肠道菌群及代谢物调控宿主肠道免疫的研究进展[J]. 生物技术通报, 2023, 39(8): 126-136. https://www.cnki.com.cn/Article/CJFDTOTAL-SWJT202308013.htm
[12]	陈说, 张帆, 范艳飞, 等. 膳食胆酸对营养性肥胖大鼠肠道炎症的改善及对肠道菌群中拟杆菌门与厚壁菌门比例的影响[J]. 胃肠病学和肝病学杂志, 2022, 31(10): 1126-1131. https://www.cnki.com.cn/Article/CJFDTOTAL-WCBX202210009.htm
[13]	Goodrich JK, Waters JL, Poole AC, et al. Human genetics shape the gut microbiome[J]. Cell, 2014, 159(4): 789-799. doi: 10.1016/j.cell.2014.09.053
[14]	Yang J, Wei H, Zhou Y, et al. High-Fat Diet Promotes Colorectal Tumorigenesis Through Modulating Gut Microbiota and Metabolites[J]. Gastroenterology, 2022, 162(1): 135-149.e2. doi: 10.1053/j.gastro.2021.08.041
[15]	Wastyk HC, Fragiadakis GK, Perelman D, et al. Gut-microbiota-targeted diets modulate human immune status[J]. Cell, 2021, 184(16): 4137-4153.e14. doi: 10.1016/j.cell.2021.06.019
[16]	Henrick BM, Rodriguez L, Lakshmikanth T, et al. Bifidobacteria-mediated immune system imprinting early in life[J]. Cell, 2021, 184(15): 3884-3898.e11. doi: 10.1016/j.cell.2021.05.030
[17]	Li M, Zhang R, Li J, et al. The Role of C-Type Lectin Receptor Signaling in the Intestinal Microbiota-Inflammation-Cancer Axis[J]. Front Immunol, 2022, 13: 894445. doi: 10.3389/fimmu.2022.894445
[18]	Lin TL, Lu CC, Lai WF, et al. Role of gut microbiota in identification of novel TCM-derived active metabolites[J]. Protein Cell, 2021, 12(5): 394-410. doi: 10.1007/s13238-020-00784-w
[19]	崔晓静, 张辉, 刘月涛, 等. 肠道菌群孵育技术及其在中药分析中的应用研究进展[J]. 分析测试学报, 2023, 42(8): 1072-1078. https://www.cnki.com.cn/Article/CJFDTOTAL-TEST202308020.htm
[20]	孔静, 王猛, 张玉华, 等. 肠黏膜机械屏障的中西医结合研究进展[J]. 中国中西医结合外科杂志, 2020, 26(5): 1001-1004. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZX202005046.htm
[21]	Sang T, Guo C, Guo D, et al. Suppression of obesity and inflammation by polysaccharide from sporoderm-broken spore of Ganoderma lucidum via gut microbiota regulation[J]. Carbohydr Polym, 2021, 256: 117594.
[22]	Gou H, Su H, Liu D, et al. Traditional Medicine Pien Tze Huang Suppresses Colorectal Tumorigenesis Through Restoring Gut Microbiota and Metabolites[J]. Gastroenterology, 2023.
[23]	Li D, Feng Y, Tian M, et al. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation[J]. Microbiome, 2021, 9(1): 83.
[24]	Huang J, Liu D, Wang Y, et al. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1(anti-PD-1/PD-L1) immunotherapy[J]. Gut, 2022, 71(4): 734-745.
[25]	Fan X, Mai C, Zuo L, et al. Erratum: Author correction to 'Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice'[Acta Pharmaceutica Sinica B 13(2023)1164-1179][J]. Acta Pharm Sin B, 2023, 13(8): 3575-3576.
[26]	Zhang ZW, Gao CS, Zhang H, et al. Morinda officinalis oligosaccharides increase serotonin in the brain and ameliorate depression via promoting 5-hydroxytryptophan production in the gut microbiota[J]. Acta Pharm Sin B, 2022, 12(8): 3298-3312.
[27]	Hong Y, Sheng L, Zhong J, et al. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice[J]. Gut Microbes, 2021, 13(1): 1-20.
[28]	Bany Bakar R, Reimann F, Gribble FM. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation[J]. Nat Rev Gastroenterol Hepatol, 2023.
[29]	吴东, 李景南, 杨爱明, 等. 胃肠激素及相关疾病的百年回眸[J]. 中国科学: 生命科学, 2021, 51(8): 920-926. https://www.cnki.com.cn/Article/CJFDTOTAL-JCXK202108007.htm
[30]	Kuang J, Wang J, Li Y, et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis[J]. Cell Metab, 2023, 35(10): 1752-1766.e8.
[31]	Hu YL, Li M, Ding L, et al. Ampelopsis grossedentata improves type 2 diabetes mellitus through modulating the gut microbiota and bile acid metabolism[J]. J Funct Foods, 2023, 107: 105622.
[32]	Le J, Zhang X, Jia W, et al. Regulation of microbiota-GLP1 axis by sennoside A in diet-induced obese mice[J]. Acta Pharm Sin B, 2019, 9(4): 758-768.
[33]	Feng R, Shou JW, Zhao ZX, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota[J]. Sci Rep, 2015, 5: 12155.
[34]	Wang Y, Tong Q, Ma SR, et al. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota[J]. Signal Transduct Target Ther, 2021, 6(1): 77.
[35]	Ma SR, Tong Q, Lin Y, et al. Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota[J]. Signal Transduct Target Ther, 2022, 7(1): 207.
[36]	Wu J, Wei Z, Cheng P, et al. Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis[J]. Theranostics, 2020, 10(23): 10665-10679.
[37]	Qian Y, Kang Z, Zhao L, et al. Berberine might block colorectal carcinogenesis by inhibiting the regulation of B-cell function by Veillonella parvula[J]. Chin Med J(Engl), 2023.
[38]	Li Q, Cui Y, Xu B, et al. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner[J]. Pharmacol Res, 2021, 170: 105694.
[39]	Liu Y, Lian X, Qin XM. Bile acid metabolism involved into the therapeutic action of Xiaojianzhong Tang via gut microbiota to treat chronic atrophic gastritis in rats[J]. Phytomedicine, 2023, 109: 154557.

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 437
PDF下载数: 91
施引文献: 0

从肠道微生态探讨中药作用机制新模式

To explore the new mode of action mechanism of Traditional Chinese Medicine from intestinal microecology

计量

目录

{{newsColumn.name}}

从肠道微生态探讨中药作用机制新模式

To explore the new mode of action mechanism of Traditional Chinese Medicine from intestinal microecology

计量

出版历程

目录

{{newsColumn.name}}